BillionToOne Shares Fall After Short-Seller Report

BillionToOne shares fell November 18, 2026, after short seller Fuzzy Panda Research alleged improper billing, undisclosed regulatory scrutiny, weaknesses in clinical claims, and reimbursement and compliance risks, including a purported Tennessee investigation. Law firm Levi & Korsinsky says it is investigating whether the company adequately disclosed billing accuracy, reimbursement risks, and regulatory inquiries; the allegations have not been established. The scrutiny follows the company’s November 4 increase to its 2026 revenue forecast of $460 million to $470 million and disclosure of $19.6 million in revenue from reprocessed prior-period claims and an approximately 112% rise in accounts receivable to $88.3 million. More than 90% of company revenue came from third-party reimbursement, according to the notice.
How it spread



